BAYER AKTIENGESELLSCHAFT 18/07/2019 13:09 BAYER AKTIENGESELLSCHAFT Strategic plans, profit forecasts and presentations Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with colorectal cancer Número de registro: 280294